Condoliase
As of the edition of 20 October 2026, Condoliase is an enzyme: marketed, first approved in 2018 (JP).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Enzyme
- Brand name
- Hernicore
- First approved
- 23 March 2018 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Seikagaku
- Registered trials
- 5, 0 stopped early
- Disease areas
- Bones, joints and muscles; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 4 | 4 | 0 | 0 |
| All trials | 5 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Seikagaku | Applicant and Lead sponsor of trials | 2007 to now |